Literature DB >> 15075524

Yellow fever vaccine is safe and effective in HIV-infected patients.

Pierre Tattevin, Agnès Geremy Depatureaux, Jean Marc Chapplain, Mathieu Dupont, Faouzi Souala, Cédric Arvieux, Jean Dominique Poveda, Christian Michelet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15075524     DOI： 10.1097/00002030-200403260-00020

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  11 in total

Review 1.  The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins; Dave Jackson; Tyler Williamson
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

Review 2.  Vaccination in HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Mark R Wallace
Journal:  AIDS Patient Care STDS       Date:  2014-07-16       Impact factor: 5.078

Review 3.  Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis.

Authors:  Solen Kernéis; Odile Launay; Clément Turbelin; Frédéric Batteux; Thomas Hanslik; Pierre-Yves Boëlle
Journal:  Clin Infect Dis       Date:  2014-01-10       Impact factor: 9.079

4.  STATEMENT FOR TRAVELLERS AND YELLOW FEVER: An Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT).

Authors:  This Statement Was Prepared By P Charlebois
Journal:  Can Commun Dis Rep       Date:  2013-03-05

5.  Statement for Travellers and Yellow Fever: Committee to Advise on Tropical Medicine and Travel.

Authors:  P Charlebois
Journal:  Can Commun Dis Rep       Date:  2010-10-02

Review 6.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

7.  Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.

Authors:  Xiaohong Jiang; Tim J Dalebout; Peter J Bredenbeek; Ricardo Carrion; Kathleen Brasky; Jean Patterson; Marco Goicochea; Joseph Bryant; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2010-12-08       Impact factor: 3.641

8.  International Travel: Recommendations for the HIV-infected Patient.

Authors:  Lisa A Spacek; Thomas C Quinn
Journal:  Curr Infect Dis Rep       Date:  2004-10       Impact factor: 3.725

Review 9.  Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II.

Authors:  Nancy F Crum-Cianflone; Eva Sullivan
Journal:  Infect Dis Ther       Date:  2017-08-05

10.  Vaccination in patients with HIV infection.

Authors:  Todd D Gleeson; Mark R Wallace; Sybil A Tasker
Journal:  Curr Infect Dis Rep       Date:  2006-03       Impact factor: 3.663
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.